Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.

Bastiaans DET, Geelen SPM, Visser EG, van der Flier M, Vermont CL, Colbers APH, Roukens M, Burger DM, van Rossum AMC; Dutch Paediatric HIV Study Group.

Pediatr Infect Dis J. 2018 Oct;37(10):1008-1010. doi: 10.1097/INF.0000000000001964.

PMID:
29474261
2.

Correction: Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.

Cohen S, Innes S, Geelen SPM, Wells JCK, Smit C, Wolfs TFW, van Eck-Smit BLF, Kuijpers TW, Reiss P, Scherpbier HJ, Pajkrt D, Bunders MJ.

PLoS One. 2018 Jan 2;13(1):e0190726. doi: 10.1371/journal.pone.0190726. eCollection 2018.

3.

Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

Weijsenfeld AM, Smit C, Cohen S, Wit FWNM, Mutschelknauss M, van der Knaap LC, van Zonneveld LM, Zomer BJ, Nauta N, Patist JC, Kuipers-Jansen MHJ, Smit EP, Blokhuis C, Pajkrt D; Dutch HIV Adolescents and Young Adults (AYA) Study Group, Weijsenfeld AM, Cohen S, Blokhuis C, van der Plas A, Scherpbier HJ, Mutschelknauss M, Nellen FJB, Prins JM, Pajkrt D, Smit C, Wit FWNM, Reiss P, van der Knaap L, Visser E, van Zonneveld LM, Vriesde ME, Bassant NY, van der Ende ME, van Rossum AMC, Driessen GJA, Fraaij PLA, Smit JV, Smit EP, Kastelijns MPW, den Hollander JG, Pogány K, Moons C, Kroon FP, Oude Geerdink E, van der Meche IB, Schouten WEM, Brinkman K, Ter Beest G, Gisolf EH, Richter C, Zomer BJ, Strik-Albers R, van der Flier M, Henriet SS, Koopmans PP, Patist JC, Nauta N, Geelen SPM, Wolfs TFW, Hoepelman IM, Mudrikova T, van der Meulen PA, de Jonge H, Scholvink EH, Bierman WFW, van den Berg JF, Bouwhuis JW, Faber S, van Vonderen M, Schippers JA, Lowe SH, Kuipers-Jansen MHJ, van Kasteren MEE, Brouwer AE, Pronk DC, Kortmann W.

Clin Infect Dis. 2016 Oct 15;63(8):1105-1112. doi: 10.1093/cid/ciw487. Epub 2016 Jul 20.

PMID:
27439528
4.

Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.

Cohen S, Innes S, Geelen SP, Wells JC, Smit C, Wolfs TF, van Eck-Smit BL, Kuijpers TW, Reiss P, Scherpbier HJ, Pajkrt D, Bunders MJ.

PLoS One. 2015 Jul 6;10(7):e0120927. doi: 10.1371/journal.pone.0120927. eCollection 2015. Erratum in: PLoS One. 2018 Jan 2;13(1):e0190726.

5.

Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected child.

Blonk MI, van Maarseveen EM, Geelen SP, Burger DM.

Clin Infect Dis. 2015 Jul 15;61(2):294-5. doi: 10.1093/cid/civ290. Epub 2015 Apr 13. No abstract available.

PMID:
25870330
6.

Country of birth does not influence long-term clinical, virologic, and immunological outcome of HIV-infected children living in the Netherlands: a cohort study comparing children born in the Netherlands with children born in Sub-Saharan Africa.

Cohen S, van Bilsen WP, Smit C, Fraaij PL, Warris A, Kuijpers TW, Geelen SP, Wolfs TF, Scherpbier HJ, van Rossum AM, Pajkrt D.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):178-85. doi: 10.1097/QAI.0000000000000431.

PMID:
25405830
7.

Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Mutwa PR, Boer KR, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, van de Wijgert J, Asiimwe A, Reiss P, Geelen SP.

PLoS One. 2014 Nov 3;9(11):e111948. doi: 10.1371/journal.pone.0111948. eCollection 2014.

8.

"Let's talk about sex": a qualitative study of Rwandan adolescents' views on sex and HIV.

Van Nuil JI, Mutwa P, Asiimwe-Kateera B, Kestelyn E, Vyankandondera J, Pool R, Ruhirimbura J, Kanakuze C, Reiss P, Geelen SP, van de Wijgert JH, Boer KR.

PLoS One. 2014 Aug 5;9(8):e102933. doi: 10.1371/journal.pone.0102933. eCollection 2014.

9.

Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda.

Mutwa PR, Boer KR, Rusine J, Muganga N, Tuyishimire D, Schuurman R, Reiss P, Lange JM, Geelen SP.

Pediatr Infect Dis J. 2014 Jan;33(1):63-9. doi: 10.1097/INF.0b013e31829e6b9f.

PMID:
24352189
10.

Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.

Cohen S, Smit C, van Rossum AM, Fraaij PL, Wolfs TF, Geelen SP, Schölvinck EH, Warris A, Scherpbier HJ, Pajkrt D; Dutch Paediatric HIV Study Group.

AIDS. 2013 Oct 23;27(16):2567-75. doi: 10.1097/01.aids.0000432451.75980.1b.

PMID:
23842124
11.

Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.

Schoffelen AF, Wensing AM, Tempelman HA, Geelen SP, Hoepelman AI, Barth RE.

PLoS One. 2013;8(3):e58526. doi: 10.1371/journal.pone.0058526. Epub 2013 Mar 11.

12.

Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.

Mutwa PR, Boer KR, Rusine JB, Muganga N, Tuyishimire D, Reiss P, Lange JM, Geelen SP.

Pediatr Infect Dis J. 2013 Mar;32(3):246-51. doi: 10.1097/INF.0b013e318271b93d.

PMID:
22976050
13.

Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.

Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57.

PMID:
22481606
14.

Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study.

Boender TS, Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Hamers RL, Nakatudde LK, Khauda E, Mukuye A, Ditai J, Geelen SP, Mugyenyi P, Rinke de Wit TF, Kityo C.

AIDS Res Treat. 2012;2012:817506. doi: 10.1155/2012/817506. Epub 2012 Feb 6.

15.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
16.

HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF.

Lancet Infect Dis. 2011 Oct;11(10):769-79. doi: 10.1016/S1473-3099(11)70141-4. Epub 2011 Aug 25. Review.

PMID:
21872531
17.

Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment.

Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP.

Pediatr Infect Dis J. 2011 Jan;30(1):52-6. doi: 10.1097/INF.0b013e3181ed2af3.

PMID:
20631647
18.

Improved general health of international adoptees, but immunization status still insufficient.

van Schaik R, Wolfs TF, Geelen SP.

Eur J Pediatr. 2009 Sep;168(9):1101-6. doi: 10.1007/s00431-008-0895-7. Epub 2009 Jan 6.

19.

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.

Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, Tempelman HA.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):977-84. doi: 10.1007/s10096-008-0534-2. Epub 2008 Jul 16.

PMID:
18629557
20.

Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging.

Vrisekoop N, van Gent R, de Boer AB, Otto SA, Borleffs JC, Steingrover R, Prins JM, Kuijpers TW, Wolfs TF, Geelen SP, Vulto I, Lansdorp P, Tesselaar K, Borghans JA, Miedema F.

J Immunol. 2008 Jul 15;181(2):1573-81.

21.

Neurocognitive function profile in HIV-infected school-age children.

Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP.

Eur J Paediatr Neurol. 2008 Jul;12(4):290-7. Epub 2007 Oct 18.

PMID:
17950012
22.

Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.

Wensing AM, Boucher CA, van Kasteren M, van Dijken PJ, Geelen SP, Juttmann JR.

AIDS. 2006 Jun 26;20(10):1465-7. No abstract available.

PMID:
16791028
23.

[Episodes of angioedema in children with C1 esterase inhibitor deficiency].

Hemels MA, Geelen SP, Hoekstra MO, Meijer Y.

Ned Tijdschr Geneeskd. 2006 Mar 18;150(11):631-4. Dutch.

PMID:
16610507
24.
25.

Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.

van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP.

J Neuroimmunol. 2005 Mar;160(1-2):170-7.

PMID:
15710470
26.

Plasma vascular endothelial growth factor in severe sepsis.

van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP.

Shock. 2005 Jan;23(1):35-8.

PMID:
15614129
27.

Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis.

van der Flier M, Hoppenreijs S, van Rensburg AJ, Ruyken M, Kolk AH, Springer P, Hoepelman AI, Geelen SP, Kimpen JL, Schoeman JF.

Pediatr Infect Dis J. 2004 Jul;23(7):608-13.

PMID:
15247597
28.

[Persistent fever of unknown origin in two young infants caused by the atypical form of Kawasaki disease].

de Ruijter FT, Wolfs TF, Geelen SP, Faber TE.

Ned Tijdschr Geneeskd. 2004 May 1;148(18):892-5. Dutch.

PMID:
15152393
29.

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM.

Antivir Ther. 2003 Jun;8(3):215-22.

PMID:
12924538
30.

Reprogramming the host response in bacterial meningitis: how best to improve outcome?

van der Flier M, Geelen SP, Kimpen JL, Hoepelman IM, Tuomanen EI.

Clin Microbiol Rev. 2003 Jul;16(3):415-29. Review.

31.

[Invasive infection with Moraxella catarrhalis in two children with lymphatic leukemia and granulocytopenia].

Ernst-Kruis MR, Rutgers MI, Révész T, Wolfs TF, Fleer A, Geelen SP.

Ned Tijdschr Geneeskd. 2003 Jun 7;147(23):1126-8. Dutch.

PMID:
12822523
32.

Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.

Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM.

Ann Pharmacother. 2003 Apr;37(4):521-5.

PMID:
12659608
33.

[Three toddlers with a swelling in the neck].

Gerrits JA, Wolfs TF, Geelen SP.

Ned Tijdschr Geneeskd. 2003 Feb 8;147(6):225-9. Dutch.

PMID:
12621974
34.

Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.

Van Rossum AM, Gaakeer MI, Verweel S, Hartwig NG, Wolfs TF, Geelen SP, Lamberts SW, de Groot R.

Pediatr Infect Dis J. 2003 Jan;22(1):70-6.

PMID:
12544412
35.

[Serious invasive pneumococcal disease in young children: the importance of vaccination].

Haveman LM, Geelen SP, Sanders EA, Wolfs TF.

Ned Tijdschr Geneeskd. 2002 Oct 12;146(41):1917-20. Dutch.

PMID:
12404904
36.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
37.

[Pneumonia due to Legionella pneumophila in an immunocompromised child].

van Dijk K, Kamphuis S, Geelen SP, Wulffraat NM, van Gestel JP, Wolfs TF.

Ned Tijdschr Geneeskd. 2002 Jul 27;146(30):1420-3. Dutch.

PMID:
12174438
38.

[HIV infection in children and the prevention of mother-to-child transmission].

Geelen SP.

Ned Tijdschr Geneeskd. 2002 Jul 6;146(27):1261-4. Dutch.

PMID:
12138669
39.

Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.

van Rossum AM, Geelen SP, Hartwig NG, Wolfs TF, Weemaes CM, Scherpbier HJ, van Lochem EG, Hop WC, Schutten M, Osterhaus AD, Burger DM, de Groot R.

Clin Infect Dis. 2002 Apr 1;34(7):1008-16. Epub 2002 Mar 4.

PMID:
11880968
40.

Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.

van Rossum AM, Scherpbier HJ, van Lochem EG, Pakker NG, Slieker WA, Wolthers KC, Roos MT, Kuijpers JH, Hooijkaas H, Hartwig NG, Geelen SP, Wolfs TF, Lange JM, Miedema F, de Groot R; Dutch Study Group for Children with HIV Infections.

AIDS. 2001 Nov 23;15(17):2267-75.

PMID:
11698700
41.

Neonatal sepsis by Campylobacter jejuni: genetically proven transmission from a household puppy.

Wolfs TF, Duim B, Geelen SP, Rigter A, Thomson-Carter F, Fleer A, Wagenaar JA.

Clin Infect Dis. 2001 Mar 1;32(5):E97-9. Epub 2001 Feb 23.

PMID:
11229867
42.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection.

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

43.

Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain.

van der Flier M, Stockhammer G, Vonk GJ, Nikkels PG, van Diemen-Steenvoorde RA, van der Vlist GJ, Rupert SW, Schmutzhard E, Gunsilius E, Gastl G, Hoepelman AI, Kimpen JL, Geelen SP.

J Infect Dis. 2001 Jan 1;183(1):149-53. Epub 2000 Nov 30.

PMID:
11106541
44.

Streptococcus pneumoniae induces secretion of vascular endothelial growth factor by human neutrophils.

van Der Flier M, Coenjaerts F, Kimpen JL, Hoepelman AM, Geelen SP.

Infect Immun. 2000 Aug;68(8):4792-4.

45.

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.

van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, Veerman AJ, Suur MH, de Graeff-Meeder ER, Slieker WA, Hop WC, Osterhaus AD, Burger DM, De Groot R.

J Pediatr. 2000 Jun;136(6):780-8.

PMID:
10839877
46.

[Team care: a necessity for a child with HIV infection].

Geelen SP, Wolfs TF, Nauta N, de Lange SM, de Graeff-Meeder ER.

Ned Tijdschr Geneeskd. 1999 Aug 14;143(33):1681-5. Dutch.

PMID:
10494306
47.

Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Neeleman C, Geelen SP, Aerts PC, Daha MR, Mollnes TE, Roord JJ, Posthuma G, van Dijk H, Fleer A.

Infect Immun. 1999 Sep;67(9):4517-24.

48.

Bordetella bronchiseptica respiratory infection in a child after bone marrow transplantation.

Choy KW, Wulffraat NM, Wolfs TF, Geelen SP, Kraaijeveld CA, Fleer A.

Pediatr Infect Dis J. 1999 May;18(5):481-3. No abstract available.

PMID:
10353531
49.

[Vertical HIV-I-transmission. II. HIV-diagnosis in a child].

Orendi JM, Geelen SP, de Graeff-Meeder ER, van Loon AM, Schuurman R, Boucher CA.

Ned Tijdschr Geneeskd. 1998 Dec 12;142(50):2724-8. Review. Dutch.

PMID:
10065236
50.

[Pertussis in young infants].

Vegelin AL, van Vught AJ, Wolfs TF, Kimpen JL, Geelen SP.

Ned Tijdschr Geneeskd. 1998 Dec 5;142(49):2657-60. Dutch.

PMID:
10065219

Supplemental Content

Loading ...
Support Center